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Abstract 
Thymic malignancies are rare intrathoracic tumors that may be aggressive and difficult to 
treat in advanced stage. Surgery is the cornerstone of the management of thymomas: it 
is significant for the definite histopathological diagnosis and staging, and in most cases, 
it constitutes the first step of the treatment strategy. For patients with primary 
unresectable thymomas, the multimodal treatment schedule nowadays includes 
neoadjuvant chemotherapy, extensive surgery, adjuvant radiotherapy, and in some 
cases, adjuvant chemotherapy. A patient with a history of stage III COPD and an 
undiagnosed thoracic mass was admitted to the intensive care unit with acute 
respiratory distress. A radiologic evaluation by CT scan revealed a mass of 13 cm in 
diameter at the mediastinum. Fine needle aspiration was performed and revealed a 
thymoma. Due to poor performance status, the patient was not able to undergo surgery. 
He refused to be treated with neither chemotherapy nor radiotherapy, but due to EGFR 
overexpression, treatment with TK inhibitor was suggested. Fine needle aspiration 
biopsy is commonly used to identify metastasis to the mediastinum. However, it is less 
often employed as a primary diagnostic tool for tumors, particularly thymic neoplasms. 
The use of targeted therapies for the treatment of thymic malignancies has been 
described in the literature. Over the past years, significant efforts have been made to 
dissect the molecular pathways involved in the carcinogenesis of these tumors. Insights 
have been obtained following anecdotal clinical responses to targeted therapies, and 
large-scale genomic analyses have been conducted. Case Rep Oncol 2011;4:155–161 
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Introduction 
Thymomas are the most common primary neoplasm of the anterior mediastinum but 
account for less than 1% of all adult malignancies [1]. Thymomas are usually slow-
growing tumors manifesting with local extension, which tend to spread along the serosal 
surfaces, i.e., along the pleura and pericardium, whereas extrathoracic metastases are 
uncommon [2]. The Masaoka staging system still remains a valuable and reproducible 
prognostic factor of thymoma. However, some proposals of revision of the staging system 
have been offered to identify significant differences in survival between each stage [3]. A 
large-scale study, which collected thymic epithelial tumors from multiple institutions in 
Japan, demonstrated that the Yamakawa and Masaoka TNM system classification (1991) 
is an excellent predictor of the prognosis of thymic epithelial tumors, including thymic 
carcinoma, in both overall and tumor-specific survival and that the N and/or M factors 
influence the prognosis more than the T factor [3]. For the subclassification of the N 
and/or M factors, large-scale studies, including resectable and unresectable tumors, are 
necessary. 
Over the past 12 years, the Lung Disease Site Group (LDSG) has produced 25 
evidence-based guidelines on various aspects of lung cancer [4]. Despite the advances in 
the treatment of thymoma that have occurred in the last two decades, there is little 
definite evidence to form guidelines of best clinical practice. Given the rare nature of 
these tumors and the multiple acceptable approaches to treatment, it was difficult for the 
LDSG to make definite recommendations. The current data do not adequately address 
certain controversial topics, which include: (1) the role of adjuvant treatment in stage II 
disease, (2) the choice, timing, and sequencing of combined modality therapy (i.e., 
surgery, radiotherapy, and chemotherapy) in stage III disease, (3) identifying for whom 
surgery is appropriate, and whether debulking surgery is appropriate in unresectable or 
disseminated disease as there is limited evidence to refute or support it, and (4) 
determining the best treatment approach to recurrent disease. At present, there is 
individual and institutional variation in the timing and sequencing of treatment and what 
extent of disease is regarded as being resectable [5]. 
Case Presentation 
A 73-year-old Caucasian male, heavy smoker (120 pack-years), was admitted to the intensive care 
unit (ICU) with acute respiratory distress, SOFA score evaluation 14, and CURB-65 score 4. The patient 
had a history of stage III COPD (FEV1, 35%pred) (GOLD ERS/ATS) and an undiagnosed mediastinal 
mass of 5 cm in diameter, which had been first diagnosed by CT scan 3 years before. At that time, the 
patient had refused further investigation of the newly discovered undiagnosed mass. Upon admission, 
blood samples were collected and chest X-ray was conducted. His temperature was 39°C, blood 
pressure: 90/70 mm Hg, heart rate: 60 beats/min, respiratory rate: 32 breaths/min and blood arterial gas 
was PO2: 45 mm Hg, PCO2: 80 mm Hg, pH: 6.50, and HCO3: 45 mmol/l with FiO2 of 21%. The 
laboratory findings were as follows: white blood count: 20,000/μl, C-reactive protein: 22 mg/dl, 
erythrocyte sedimentation rate: 25 mm, procalcitonin: 2 ng/ml, urea: 59 mg/dl, creatinine: 0.8 mg/dl, K: 
4.1 mmol/l, Na: 138 mmol/l, SGOT: 23 U/l, SGPT: 39 U/l, LDH: 204 U/l, CPK: 15 U/l, ALP: 196 U/l, g-
GT: 103 U/l. Blood cultures were negative, but urine antigen for Streptococcus pneumoniae was positive. 
His X-ray presented a small pleural effusion on the left hemithorax, but the significant finding was the 
dilated upper mediastinum. The patient was intubated and admitted to the ICU. A CT scan of the 
thorax was performed to evaluate the dilated mediastinum. The undiagnosed mass had an increased 
size, measuring 13 cm in diameter (fig. 1). Case Rep Oncol 2011;4:155–161 
DOI: 10.1159/000327091 
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Initially, he was treated with a double antibiotic regimen consisting of ceftriaxone and ciprofloxacin 
for 7 days. After the 7-day regimen, he became afebrile, and we decided to perform a fine needle 
aspiration (FNA) biopsy (fig. 2), instead of choosing the usual surgical method [3, 6, 7]. The biopsy 
result was positive for EGFR expression by immunohistochemistry, and was consistent with the 
diagnosis of thymic carcinoma. According to the Masaoka staging system, the patient’s stage was IVa.  
The anesthesiologists and thoracic surgeons of our hospital decided that the patient was not a 
candidate for surgery: based on the stage III COPD with FEV1 (35%pred) and an elevated post-
intubational PCO2 of 60 mm Hg during daytime, he would not be able to wean off the mechanical 
ventilation after surgery. Although, multiple chemotherapy regimens with or without radiotherapy have 
been well established or administered experimentally, we decided to treat the patient with the TK 
inhibitor gefinitib [5, 8, 9]. The patient had a successful weaning from the mechanical ventilation, but he 
remained on noninvasive positive airway pressure ventilation, with a full face mask with continuous 
positive airway pressure (CPAP) (17 cm H2O pressure/24 h daily). He was discharged with a portable 
CPAP device. During the next 4 months, he received gefinitib (250 mg/daily) and his disease remained 
stable as judged by CT scan evaluation (fig. 3). We cannot be certain whether the tumor did not 
increase in size due to TK inhibitor administration or due to its slow growth, we can only speculate that 
the TK inhibitor administration had a positive effect because of the positive expression of the EGFR.  
We decided that the patient should receive anticoagulation therapy with low-molecular weight 
heparin systematically in a daily prophylactic dose, since he would remain bedridden for a prolonged 
time. Unfortunately, the patient died at home on the fifth month after his hospital discharge, and the 
autopsy revealed massive pulmonary embolism. 
Discussion 
Thymomas usually present in the fourth and fifth decades of life [10, 11].
 There is no 
clear sex predisposition. One third to one half of patients present with an asymptomatic 
anterior mediastinal mass on chest radiograph, one third present with local symptoms 
(e.g., cough, chest pain, superior vena cava syndrome, and/or dysphagia), and one third of 
cases are detected during the evaluation of myasthenia gravis. Distant metastases are 
distinctly uncommon at initial presentation of this tumor. However, when present, the 
most common metastatic site is the pleura, with involvement of the kidney, bone, and 
liver; brain metastases are infrequently seen. 
The diagnostic work-up after CT scan usually includes surgical excision, which 
provides the precise histological and staging information necessary for the next 
therapeutic steps. The most common tumors that the clinician must include in the 
differential diagnosis of an anterior mediastinal tumor are lymphomas and germ cell 
tumors [11, 12]. 
FNA biopsy is commonly used to document metastasis to the mediastinum. It is less 
often used to make the primary diagnosis of tumors, particularly thymic neoplasms. This 
is due to problems of sampling error, rarity of thymic tumors, multiplicity of lesions in 
the mediastinum, and inexperience on the part of the cytopathologist. A common 
problem that clinical physicians and pathologists have to face when using FNA for biopsy 
is the small amount of material obtained. This disadvantage of the FNA technique has a 
serious impact on the result. The big ‘small sample problem’ will be encountered more 
and more nowadays, since less invasive procedures like FNA are more frequently 
preferred and, like in our case, they are successful in providing information regarding 
EGFR-expression status. The same problem is also encountered for lung cancer biopsies, 
where the obtained biopsy specimens are very small, and in most of the cases, the EGFR-
positive mutation depends entirely on the ‘right’ area of the tumor where the biopsy is Case Rep Oncol 2011;4:155–161 
DOI: 10.1159/000327091 
Published online: 
March 22, 2011 
© 2011 S. Karger AG, Basel
ISSN 1662–6575 
www.karger.com/cro   
 
 
 
158
performed. Nevertheless, EGFR mutations are rare and a second biopsy should not be 
repeated unless the first is not positive for malignancy. 
Targeted therapy with TK inhibitors (erlotinib-Tarceva and gefinitib-Iressa) is a well-
established therapy for EGFR-positive mutation tumors. However, a question remains to 
be answered: Which of the two inhibitors is more efficient? This clinically based 
assumption remains to be discussed within larger studies. Furthermore, patients who 
present intense rush due to the TK inhibitor therapy seem to respond positively to this 
kind of treatment in comparison to patients who do not present intense rush. These 
patients show better results with smaller doses of TK inhibitors [13, 14].
 Our patient did 
not present rushes, and unfortunately, although he was under low-molecular weight 
heparin, a massive pulmonary embolism occurred. This kind of event is expected to occur 
in patients with an extensive tumor burden [15]. 
Further studies with larger patient series evaluating whether this form of treatment is 
applicable to this type of cancer are needed. Small case studies or published case reports 
present conflicting data: some demonstrate stable disease or response to TK inhibitors, 
while others report disease progression [14, 15]. In addition to EGFR, other parameters 
could be evaluated in histopathologic specimens such as RAF, VEGFR, PDGFR, c-KIT, 
FLT-3, HDACs and p38, and as a result, more treatment modalities could be explored and 
established as therapy [8]. 
In conclusion, we are convinced that this form of treatment could be applied in thymic 
tumors, as shown in published data. However, studies with larger patient series are yet to 
be completed. In addition, more parameters from systematic analyses of the genetic 
aberration profiles of these tumors remain to be explored to evaluate the efficacy of other 
treatment modalities. 
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Fig. 1. CT scan of the mass located at the mediastinum, measuring 13 × 7 cm. 
 
 
 
Fig. 2. CT-guided FNA of the mass. 
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Fig. 3. CT scan reevaluation after 4 months. 
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